142 related articles for article (PubMed ID: 25940947)
21. Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes.
Saad AA; Awed NM; Abdel-Hafeez ZM; Kamal GM; Elsallaly HM; Alloub AI
Saudi Med J; 2010 Feb; 31(2):135-41. PubMed ID: 20174727
[TBL] [Abstract][Full Text] [Related]
22. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
[TBL] [Abstract][Full Text] [Related]
23. Tissue microarray in a subset of South African patients with DLBCL.
Sissolak G; Wood L; Smith L; Chan JW; Armitage J; Jacobs P
Transfus Apher Sci; 2013 Oct; 49(2):120-32. PubMed ID: 23942329
[TBL] [Abstract][Full Text] [Related]
24. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
[TBL] [Abstract][Full Text] [Related]
25. [The clinical characteristics and prognostic analysis of 147 cases of diffuse large B-cell lymphoma].
Zhao Q; Fu WJ; Zhang CY; Du J; Xi H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):737-40. PubMed ID: 24103868
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of mTOR in germinal center and nongerminal center group of diffuse large B-cell lymphoma: a clinicopathological study.
Vajpayee N; Burack R; Wang D; Hutchison RE; Gajra A
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):159-63. PubMed ID: 25458080
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas--a review article.
Jabłońska J; Jesionek-Kupnicka D
Pol J Pathol; 2008; 59(3):121-7. PubMed ID: 19097355
[TBL] [Abstract][Full Text] [Related]
28. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
Wen JJ; Liu ZB; Xu J; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
[TBL] [Abstract][Full Text] [Related]
29. Primary breast diffuse large B-cell lymphoma shows an activated B-cell-like phenotype.
Li D; Deng J; He H; Bu Y; Peng F; Tang X; Wang B; Lei Y; Zhang H; Xie P
Ann Diagn Pathol; 2012 Oct; 16(5):335-43. PubMed ID: 22569408
[TBL] [Abstract][Full Text] [Related]
30. Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay.
Kim SJ; Sohn I; Do IG; Jung SH; Ko YH; Yoo HY; Paik S; Kim WS
Ann Hematol; 2014 Mar; 93(3):437-47. PubMed ID: 23975159
[TBL] [Abstract][Full Text] [Related]
31. [Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].
Miyazaki K
Rinsho Ketsueki; 2015 Oct; 56(10):2047-55. PubMed ID: 26458444
[TBL] [Abstract][Full Text] [Related]
32. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era.
Cerhan JR; Natkunam Y; Morton LM; Maurer MJ; Asmann Y; Habermann TM; Vasef MA; Cozen W; Lynch CF; Allmer C; Slager SL; Lossos IS; Chanock SJ; Rothman N; Hartge P; Dogan A; Wang SS
Leuk Lymphoma; 2012 Jun; 53(6):1105-12. PubMed ID: 22066713
[TBL] [Abstract][Full Text] [Related]
33. A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.
Michaelsen TY; Richter J; Brøndum RF; Klapper W; Johnsen HE; Albertsen M; Dybkær K; Bøgsted M
Blood Adv; 2018 Jul; 2(13):1542-1546. PubMed ID: 29967255
[TBL] [Abstract][Full Text] [Related]
34. [Expression and significance of p53-inducible gene 3 (PIG-3) in diffuse large B cell lymphoma].
Zhu F; Zhang LQ; Gu WJ; Zhu W; Guo YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):396-8. PubMed ID: 23628040
[TBL] [Abstract][Full Text] [Related]
35. A Pooled Analysis of The Clinical Utilities of Long Non-Coding RNA Based Molecular Signature for Diffuse Large B Cell Lymphoma.
Xu P; Chen X; Su P
Clin Lab; 2017 Nov; 63(11):1831-1840. PubMed ID: 29226652
[TBL] [Abstract][Full Text] [Related]
36. The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma.
Gualco G; Bacchi LM; Domeny-Duarte P; Natkunam Y; Bacchi CE
Mod Pathol; 2012 Nov; 25(11):1439-45. PubMed ID: 22743653
[TBL] [Abstract][Full Text] [Related]
37. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling.
Mosquera Orgueira A; Díaz Arias JÁ; Cid López M; Peleteiro Raíndo A; Antelo Rodríguez B; Aliste Santos C; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; González Pérez MS; Pérez Encinas MM; Fraga Rodríguez MF; Bello López JL
BMC Cancer; 2020 Oct; 20(1):1017. PubMed ID: 33087075
[TBL] [Abstract][Full Text] [Related]
38. Expression of NOTCH3 exon 16 differentiates Diffuse Large B-cell Lymphoma into molecular subtypes and is associated with prognosis.
Jespersen DS; Schönherz AA; Due H; Bøgsted M; Sondergaard TE; Dybkær K
Sci Rep; 2019 Jan; 9(1):335. PubMed ID: 30674940
[TBL] [Abstract][Full Text] [Related]
39. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?
Scott DW
Am Soc Clin Oncol Educ Book; 2015; ():e458-66. PubMed ID: 25993210
[TBL] [Abstract][Full Text] [Related]
40. Algorithmic fusion of gene expression profiling for diffuse large B-cell lymphoma outcome prediction.
Zhu Q; Cui H; Cao K; Chan WC
IEEE Trans Inf Technol Biomed; 2004 Jun; 8(2):79-88. PubMed ID: 15217252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
